Table 5.
Cox multivariable model of factors jointly predicting survival.a
| P-value | Hazard ratio | 95% CI | |
|---|---|---|---|
| Erythema BSA% | 0.053 | 1.995 | 0.992–4.013 |
| LFS | 0.0017 | 3.436 | 1.591–7.421 |
| KPS | 0.013 | 0.413 | 0.206–0.828 |
| Time from cGVHD Dx | 0.0060 | 0.186 | 0.0056–0.617 |
| Eosinophil count | 0.0018 | 3.960 | 1.672–c9.381 |
Abbreviations: BSA% = body surface area %; CI = confidence interval; Dx = diagnosis; KPS = Karnofsky performance score; LFS = lung function score. In addition to the ‘Form A’ and ‘Form B’ measures (P-values in Supplementary Table 2), other variables considered for inclusion in the final Cox model were time from walk distance in 2 min ( < = 438 vs >438 feet: P = 0.025 unadjusted; P = 0.074 adjusted); time from transplant to enrollment ( < = 60.5 months vs >60.5 months: P = 0.021 unadjusted, P = 0.063 adjusted); platelets ( < = 100 vs >100: P = 0.56); cGVHD onset (progressive vs quiescent+de novo: P = 0.48); age ( < = 40 vs >40: P = 0.40); NIH skin score (0–2 vs 3: P = 0.0173).
Categories used for comparison: erythema BSA % (0–3% vs >3%: p 0.0006 adjusted, P = 0.0018 unadjusted); LFS ( 2–7 vs 8–12: P = 0.0047 unadjusted, P = 0.014 adjusted); KPS (30–70 vs 80–100: P <0.0001 unadjusted, P <0.0001 adjusted); time from cGVHD Dx (diagnosis) to enrollment ( < = 49 months vs>49 months: P = 0.021 unadjusted, P = 0.063 adjusted); eosinophils: < = 0.5 vs >0.5: P = 0.0035).